Preventing lung adenocarcinoma using a specific drug called ONC201
TASK ORDER TITLE: PREVENTING LUNG ADENOCARCINOMA (LUAD) USING TRAIL INDUCING AGENT, ONC201BASE CONTRACT TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT
This study is looking at how well a drug called ONC201 can help prevent lung adenocarcinoma, a common type of lung cancer, by targeting cancer cells without harming normal cells, and it's for people who are at high risk for developing lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10705393 on NIH RePORTER |
What this research studies
This research focuses on preventing lung adenocarcinoma, a common type of lung cancer, by using a drug known as ONC201. The drug works by selectively targeting cancer cells, inducing cell death while sparing normal cells, which could lead to fewer side effects. The study aims to evaluate the effectiveness of ONC201 in reducing tumor growth and improving outcomes for patients at high risk for lung cancer. Participants may receive the drug in a controlled setting to monitor its safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals at high risk for lung adenocarcinoma, particularly those with specific genetic mutations or pre-existing lung conditions.
Not a fit: Patients with advanced lung cancer or those who do not meet the high-risk criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new preventive treatment for lung adenocarcinoma, potentially improving survival rates and quality of life for at-risk patients.
How similar studies have performed: Previous studies have shown promising results with similar drugs targeting cancer cell apoptosis, indicating potential for success in this approach.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Rao, Chinthalapally — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Rao, Chinthalapally
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.